ALK and non-small cell lung carcinoma: In summary, this retrospective study showed that the combination of nivolumab and docetaxel demonstrated a meaningful improvement in progression-free survival and overall survival, in patients with NSCLC after the failure of platinum doublet chemotherapy, irrespective of EGFR/ALK variation status.